Early Bird Update: All Eyes On Quantum BioPharma (NASDAQ: QNTM) In Today’s Pre-Market

*Sponsored by Quantum BioPharma Ltd. Just Announced! Quantum BioPharma (QNTM) Is Our Next Potential Breakout Idea! See Why Quantum BioPharma (QNTM) Is Topping Our Watchlist This Morning… Quantum BioPharma (NASDAQ: QNTM) Comes Backed By Several  Potential Catalysts Including: Limited Float: With fewer than 1.6Mn shares, Quantum BioPharma Ltd. (NASDAQ: QNTM)’s small float could lead to significant swings if demand begins to shift. Bullish Analyst Target: Singular Research’s $12.80 target suggests over 300% potential upside from yesterday’s $3.18 opening. Technicals Point to Oversold: RSI readings indicate potential oversold conditions, often signaling trend reversals. Clinical Development Progress: The Phase 1 trial for Lucid-21-302 (Lucid-MS) advances with ethics approval for multiple ascending dose studies. Growing MS Market: The multiple sclerosis market is projected to grow from $21B in 2024 to $38B by 2032, positioning Lucid-MS in a high-growth area. Under-the-Radar : With a market cap under $6.5Mn , Quantum BioPharma Ltd. (NASDAQ: QNTM) appears to be flying under the radar, until now. December 20, 2024 Dear Reader, In the ever-evolving biotech industry, milestones like clinical trial advancements signal not only progress but also a company’s ability to get noticed.  Quantum BioPharma Ltd. (NASDAQ: QNTM) has recently reached a pivotal moment in its mission to transform the treatment of neurological disorders.  Through its subsidiary, HUGE Biopharma Australia Pty Ltd., the company announced that the safety review committee has greenlit the second cohort dosing in its Phase 1 trial for Lucid-21-302 (Lucid-MS).  This recommendation comes after thorough evaluation of safety and pharmacokinetic data from the first cohort—an achievement that underscores Quantum BioPharma Ltd. (NASDAQ: QNTM)’s commitment to safety and scientific rigor. The ongoing clinical trial, titled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” represents a critical step in Quantum BioPharma Ltd. (NASDAQ: QNTM)'s journey to address multiple sclerosis (MS) and other demyelinating diseases.  Following the successful review of data from the first cohort, the trial's safety review committee has recommended moving forward with the next phase of dosing. Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum, expressed the team's enthusiasm, noting that dosing for the second cohort is expected to begin in the coming days. This progress is more than just a procedural update—it’s a testament to Quantum BioPharma Ltd. (NASDAQ: QNTM)’s ability to navigate the complexities of clinical development with precision and care.  This advancement is not merely a checkpoint in the clinical trial timeline—it’s a signal that Quantum BioPharma is steadily building momentum in its quest to lead the future of neurological treatments.  Keep reading to see why Quantum BioPharma Ltd. (NASDAQ: QNTM) is #1 on our watchlist this morning.  Quantum BioPharma Ltd. (NASDAQ: QNTM) recently launched a massive $700Mn lawsuit against several well-known institutions, accusing them of manipulation through "spoofing."   This announcement could set the stage for significant developments ahead.  Quantum BioPharma (NASDAQ: QNTM), with its market cap currently under $6.5M, may have been flying under Wall Street's radar—until now. After trending down to $3.15 yesterday, Quantum BioPharma (NASDAQ: QNTM) now appears “Severely Oversold” and is worth considering for a potential reversal. To assess whether a company is oversold, Wall Street often turns to the Relative Strength Index (RSI) — a widely trusted momentum indicator. The RSI measures the speed and magnitude of movements to identify overbought and oversold conditions, as well as potential reversal points.  It is plotted on a scale of 0 to 100, with readings below 30 signaling oversold conditions and readings above 70 indicating overbought territory. When RSI falls below 30, the company has entered oversold territory, which can signal a potential reversal. Here are several of Quantum BioPharma (NASDAQ: QNTM)’s current RSI levels at the time of this writing on 12/19 according to Barchart: 9-Day: 19.80% 14-Day: 27.97% 20-Day: 34.30% What makes this even more compelling is that Quantum BioPharma (NASDAQ: QNTM) has a float of less than 1.6Mn shares, according to FinViz. Companies with small floats like this are often highly volatile, and if demand shifts, this scarcity of available shares can lead to the potential for significant swings.  Adding to this is the recognition from an analyst who started to take notice of the company’s momentum and prospects. Singular Research recently reiterated its bullish rating on Quantum BioPharma (NASDAQ: QNTM), setting a target of $12.80 per share. This suggests a potential upside of over 300% from yesterday’s opening of $3.18, underscoring analysts' confidence in the company’s future performance. From oversold technicals to explosive upside potential, Quantum BioPharma (NASDAQ: QNTM) has everything analysts look for in a company with breakout potential. With its small float, RSI trending in what appears to be oversold territory, analyst coverage, and potential for growth, Quantum BioPharma (NASDAQ: QNTM) checks all the boxes we look for in a profile. Let’s Dive Deeper Into Quantum BioPharma (NASDAQ: QNTM) Quantum BioPharma (NASDAQ: QNTM) is leading the way in biopharmaceutical innovation, focusing on groundbreaking treatments for neurodegenerative and metabolic disorders, along with solutions for al-co-hol misuse.  With a diverse portfolio of candidates at various stages of development, the company is committed to addressing some of the most complex medical challenges. Through its subsidiary, Lucid Ps-ych-eceu-ticals Inc., Quantum BioPharma (NASDAQ: QNTM) is making significant progress with its lead compound, Lucid-MS, which plays a key role in the company’s mission to combat serious disorders affecting many people worldwide. One of their most promising initiatives, Lucid-MS, is a patented chemical entity designed to target multiple sclerosis (MS), a chronic, often disabling disease that affects approximately 2.8Mn people globally.  The multiple sclerosis therapeutic market is projected to grow from $21B in 2024 to $38B by 2032, underscoring the increasing need for effective treatments for this debilitating condition.  Lucid-MS is designed to address the underlying cause of MS by preventing and reversing myelin degradation.  Myelin is a protective sheath that covers nerve fibers, and its degradation is a key mechanism in the development of multiple sclerosis.  Preclinical models have shown that Lucid-MS is a neuroprotective compound with the potential to halt or reverse myelin damage, offering hope for improved outcomes for those affected by MS and other neurodegenerative conditions. Revolutionizing Al-co-hol Detoxification Quantum BioPharma (NASDAQ: QNTM) is making notable advancements in the al-co-hol detox space with the development of unbuzzd™, a product designed to boost mental alertness and aid detoxification after al-co-hol consumption.  This innovative solution addresses a pressing public health issue, blending scientific research with practical applications in al-co-hol metabolism. In 2023, unbuzzd™ was introduced to the market by Celly Nutrition Corp., a spin-off of Quantum BioPharma (NASDAQ: QNTM), with the company retaining a 25.71% stake.  The product, created by industry leaders from Coca-Cola and Celsius Holdings, has already secured a major distribution agreement with FUSION Distribution Group, bringing unbuzzd™ to Puerto Rico, the Caribbean, and parts of Central and South America.  Currently available as Ready-to-Mix powder sticks on Amazon, unbuzzd™ will soon be available in Ready-to-Drink cans. With distribution set to expand through major retailers like Walmart and Costco, unbuzzd™ is positioned to transform the al-co-hol detox market by providing a much-needed solution for consumers seeking to metabolize al-co-hol faster and enhance mental clarity. Endorsed by Kevin Harrington, one of the original "Sharks" on Shark Tank and a seasoned entrepreneur in health and wellness, unbuzzd™ has attracted significant attention for its potential impact.  Harrington, renowned for identifying groundbreaking products, believes unbuzzd™ could change how society approaches al-co-hol consumption and detoxification. Harrington remarked on the product’s potential, noting that unbuzzd™ could offer a vital solution for those who consume al-co-hol, with the ability to reduce its harmful effects and improve lives on a large scale. In his testimonial, Harrington recalled a real-life example, saying, “I saw someone intoxicated take this product. Within minutes, their demeanor shifted, and their blood al-co-hol levels dropped. unbuzzd™ has the power to revolutionize the al-co-hol detox space.” With a strong focus on advancing solutions for multiple sclerosis, neurodegenerative diseases, and al-co-hol misuse, Quantum BioPharma (NASDAQ: QNTM) continues to solidify its role in biopharmaceutical innovation. As the company expands its portfolio of transformative treatments, its ongoing progress in these areas warrants close attention. Consider Adding Quantum BioPharma (NASDAQ: QNTM) To  Your Radar This Week… Quantum BioPharma (NASDAQ: QNTM) stands out for us and deserves a closer look.. Its small float of less than 1.6Mn shares sets the stage for potentially significant swings if demand begins to shift. Singular Research’s bullish $12.80 target, suggesting over 300% upside potential from yesterday’s $3.18 opening, further highlights why it's at the top of our radar. Technicals add to the narrative, with RSI indicators signaling oversold conditions that could point to a trend reversal. Meanwhile, the company’s clinical progress with Lucid-MS positions it to tap into the rapidly expanding multiple sclerosis market, projected to reach $38B by 2032. unbuzzd™ is gaining traction internationally with major endorsements and growing retail availability, adding another layer of growth potential. Despite these advancements, Quantum BioPharma (NASDAQ: QNTM) remains relatively unnoticed with its market cap under $6.5Mn .  This combination of promising fundamentals, technical signals, and a small float could make Quantum BioPharma (NASDAQ: QNTM) one company to keep an eye on.   7 reasons to consider adding Quantum BioPharma (NASDAQ: QNTM) to your watchlist this morning…  1. Limited Float: With fewer than 1.6Mn shares available, Quantum BioPharma (NASDAQ: QNTM)’s small public float could lead to the potential for significant swings if demand begins to shift.  2. Bullish Analyst Target: Singular Research set a $12.80 target for Quantum BioPharma (NASDAQ: QNTM), which suggests over 300% upside potential from its $3.18 opening yesterday. (12/19) 3. Technicals Point to Oversold: RSI indicators suggest Quantum BioPharma (NASDAQ: QNTM) could be headed towards “oversold territory”, often a signal for potential trend reversals.   4. Momentum in Clinical Development: The Phase 1 trial for Lucid-21-302 (Lucid-MS) is advancing with ethics approval for multiple ascending dose studies, marking important progress. 5. Tapping a Growing Market: The multiple sclerosis treatment market is projected to grow from $21B in 2024 to $38B by 2032, positioning Lucid-MS in a high-growth space. 6. unbuzzd™ Poised for Growth: Backed by Kevin Harrington and major distribution agreements, unbuzzd™ is expanding into international markets with future availability at large retailers. 7. Flying Under the Radar: With a market cap under $6.5Mn , Quantum BioPharma (NASDAQ: QNTM) appears to be an overlooked player despite its recent advancements. Consider pulling up Quantum BioPharma (NASDAQ: QNTM) and starting your research while it’s still early.  Quantum BioPharma (NASDAQ: QNTM) is topping our radar right now and we have all eyes on it this morning. I’m dead serious. Take a look at (QNTM) before the opening bell rings. I’ll check back in with you shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Quantum BioPharma Ltd., TD Media LLC has been hired for a period beginning on 12/19/2024 and ending on 12/20/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, we have been paid fifty-five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer. To date, including under the previously described agreement, TD Media LLC has been paid three hundred fifty thousand USD (“Funds”) for (QNTM:US). TD Media LLC does not own shares of (QNTM:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/qntm/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice